Once dear to the investing community like artificial intelligence is nowadays, stocks in the biotech space do not grab as much attention these days. Damning incidents of data breaches at companies like 23andMe (MEHCQ) and fraud against the management of Theranos spooked investors so much that shares of the State Street SPDR S&P Biotech ETF (XBI)—the biggest ETF covering the biotech sector—are down 13% over five years.
Yet, the biotech industry remains an exciting investment prospect, with the sector projected to reach a size of $3.9 trillion by 2030 and about $8 trillion by 2035.
